Michael D., Support Analyst at Sarah Cannon Research Institute, shared a post by Vivek Subbiah on LinkedIn, adding:

“Meet the Master-Hands of Medicine. With the help of these doctors I was able to receive the nation’s rare heart-shaped herb, which has endowed me with enhanced strength, life, and stamina. I am forever grateful to have such extraordinary physicians.”

Quoting Vivek Subbiah’s post:

“Hot off the press huge milestone in all of medicine and huge win for patients and families with sickle cell disease and β-Thalassemia.

Today, two back to back papers published with an editorial in the New England Journal of Medicine on the First Gene Therapies to treat patients with Sickle Cell Disease and β-Thalassemia.

Meet Haydar Frangoul, Director of Stem Cell Transplant, Sarah Cannon Research Institute The Children’s Hospital at Tristar Centennial, Nashville, TN who spearheaded the CRISPR-Cas9 clinical trials.

Meet Michael D. – Thanks to real life super heroes like Mike for enrolling and volunteering in the CRISPR gene therapy clinical trial for sickle cell disease. FDA approved this ground breaking gene therapy.

This is the why we do what we do- to make life-changing breakthroughs possible.

Link to FDA approval, Link to NEJM papers for sickle cell anemia,β-Thalassemia and Link to an amazing patient story.”

Source: Michael D./LinkedIn and Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.